Novo Nordisk lowers sales outlook, investors file class action lawsuit.

• Novo Nordisk class action lawsuit filed over securities fraud allegations • Investors advised to contact Danielle Peyton or 888.4-POMLAW • Class action concerns possible unlawful business practices • Shareholders have until September 30, 2025, to request Lead Plaintiff appointment • Complaint available at pomerantzlaw.com • Novo Nordisk lowers sales outlook on July 29, 2025 • Digital data not directly mentioned in the article

Investors of Novo Nordisk A/S (NYSE: NVO) are advised to take note of a recent securities class action lawsuit filed against the company. The lawsuit alleges that Novo Nordisk made materially false and misleading statements, as well as failed to disclose adverse facts about its business, operations, and prospects. The class action is seeking damages on behalf of investors who purchased or otherwise acquired Novo Nordisk securities between May 7, 2025, and July 28, 2025, inclusive [1].

The lawsuit specifically alleges that Novo Nordisk overestimated its ability to capture patients coming off of compounded treatments, a significant unmet patient population, and downplayed the significance of the personalization exception for GLP-1 compounding. These alleged misrepresentations led to a significant drop in Novo Nordisk's stock price on July 29, 2025, when the company revised its 2025 sales growth and operating profit forecasts [1].

Investors with losses on their Novo Nordisk investments are encouraged to contact Danielle Peyton at Pomerantz LLP to discuss their legal rights and options. The deadline to request appointment as lead plaintiff in the class action is September 30, 2025 [3]. A copy of the Complaint can be obtained at www.pomerantzlaw.com [3].

The lawsuit is one of several recent legal challenges facing Novo Nordisk. In addition to the securities fraud allegations, Novo Nordisk has faced regulatory scrutiny and competition from other pharmaceutical companies, such as Eli Lilly, which has developed tirzepatide-based drugs [4].

Investors are advised to carefully consider the risks and rewards of investing in Novo Nordisk, particularly given the company's reliance on a single therapeutic class and the potential for regulatory challenges. Diversification and a balanced investment strategy are recommended to mitigate these risks [4].

References:
[1] https://www.morningstar.com/news/globe-newswire/9510605/deadline-alert-novo-nordisk-as-nvo-investors-who-lost-money-urged-to-contact-glancy-prongay-murray-llp-about-securities-fraud-lawsuit
[2] https://www.globenewswire.com/news-release/2025/08/11/3130907/0/en/SHAREHOLDER-ALERT-Bernstein-Liebhard-LLP-Announces-A-Securities-Fraud-Class-Action-Lawsuit-Has-Been-Filed-Against-Novo-Nordisk-A-S-NYSE-NVO.html
[3] https://www.morningstar.com/news/pr-newswire/20250811dc47712/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-rocket-pharmaceuticals-inc-of-class-action-lawsuit-and-upcoming-deadlines-rckt
[4] https://www.ainvest.com/news/securities-litigation-glp-1-gold-rush-assessing-novo-nordisk-risks-rewards-2508/